Keywords: fda, issues, advisory, influenza, treatments, height, season

FDA issues advisory on influenza treatments

Article | 19 January 2000

Print This

At the height of the influenza season and amid the marketing pushes byGlaxo Wellcome and Hoffmann-La Roche for Relenza (zanamivir) ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in